Fulcrum Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
27.4%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.76next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly333.3MTarget: Capital preservation during strategic review
Full-Time Employee Headcount Quarterly9.0Target: 9 (following 85% workforce reduction)
Restructuring Charges Quarterly4.2MTarget: Substantially completed in Q2 2026
Watch Items
- Strategic Review OutcomeTrigger: Announcement of merger, acquisition, asset sale, or liquidationAction: Evaluate transaction terms against the cash-backed floor value of the company.
- Executive Retention and TransitionTrigger: Departure of remaining key executives (CEO Alex Sapir or CLO Curtis Oltmans)Action: Assess operational continuity and leadership stability during the wind-down or transition phase.
Research as of 19 Jun 2026